Rosa Carrera
Cardiovascular Disease · Brooklyn, NYNPI 1780617407
Payments from drug & device makers
Across 232 payments — averaging $40.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- E.r. Squibb & Sons, L.L.C.$1K
- Boehringer Ingelheim$868
- AbbVie$494
- Merck$455
- Amarin Pharma, Inc.$400
- plus $3K from 23 others
What the payments were for
- Food & beverage$9,456100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $3,040 |
| E.r. Squibb & Sons, L.L.C. | 41 | $1,284 |
| Boehringer Ingelheim | 14 | $868 |
| AbbVie | 8 | $494 |
| Merck | 20 | $455 |
| Amarin Pharma, Inc. | 10 | $400 |
| GSK | 3 | $357 |
| Johnson & Johnson | 14 | $312 |
| Regeneron Healthcare Solutions, Inc. | 6 | $311 |
| Boston Scientific | 6 | $309 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $250 |
| Novartis | 11 | $204 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $200 |
| Edwards Lifesciences | 9 | $171 |
| Medtronic | 3 | $159 |
| Lilly USA, LLC | 1 | $125 |
| Alnylam Pharmaceuticals Inc. | 6 | $124 |
| Medicomp Inc | 3 | $87 |
| Actelion Pharmaceuticals US, Inc. | 3 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,456 in reported general payments places this provider in the 75th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Brooklyn
- Ronald WhartonBrooklyn$1.1M
- Ozgen DoganBrooklyn$404K
- Warren WexelmanBrooklyn$396K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.